BioProtection Systems Corporation

2901 S LOOP DR STE 3360
Ames, IA 50010
60 Employees

SBIR Award Summary

Total Number of Awards 5
Total Value of Awards $1.55MM
First Award Date 05/05/08
Most Recent Award Date 04/01/11

Key Personnel

Last Name Name Awards Contact
Flick Dr. Ramon Flick 5 Message

5 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-115
Budget: 04/01/11 - 03/31/13

DESCRIPTION (provided by applicant): Indigenous population, travelers and troops present in Africa and South America are clearly at risk of exposure to several arenaviruses. Several human pathogenic arenaviruses, e.g., Lassa and Junin viruses, are listed on the NIAID's Priority Pathogens and CDC's Bioterrorism Agents Lists and can cause a deadly...

Phase 1 SBIR

Agency: Department of Agriculture
Topic: 8.3-2011
Budget: 01/01/11 - 12/31/11

This application addresses the USDA NIFA "Global Food Security and Hunger" primary societal challenge area by developing a countermeasure against a potential agricultural disease threat - Rift Valley fever virus (RVFV). RVFV is an arthropod-borne pathogen that often results in severe morbidity and mortality in both humans and livestock. RVF mani...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-115
Budget: 04/06/10 - 03/31/11

DESCRIPTION (provided by applicant): Indigenous population, travelers and troops present in Africa and South America are clearly at risk of exposure to several arenaviruses. Several human pathogenic arenaviruses, e.g., Lassa and Junin viruses, are listed on the NIAID's Priority Pathogens and CDC's Bioterrorism Agents Lists and can cause a deadly...

Phase 2 SBIR

Agency: Chemical and Biological Defense Program
Topic: CBD08-105
Budget: 07/31/09 - 07/31/11

We hypothesize that the application of the broad-spectrum immune-stimulatory and -modulatory HyperAcute alphaGal Adjuvant Technology will enhance the potency and effectiveness of VEEV vaccine candidates. To complement the exciting preclinical and clinical results obtained with alphaGal-modified anti-cancer vaccines, and preclinical studies with ...

Phase 1 SBIR

Agency: Chemical and Biological Defense Program
Topic: CBD08-105
Budget: 05/05/08 - 11/05/08

The objective of this study is to demonstrate the efficacy and broad applicability of the human immune-modulating alphaGal Adjuvant Technology for antiviral vaccine development. We will use viral vaccine candidates for the select Category A viral pathogens Zaire ebolavirus (ZEBOV, filovirus), Rift Valley fever virus (RVFV, bunyavirus), and Lassa...